#1 Clinical Trials Search in Europe

Autologous Cd34+ Hematopoietic Stem Cells Transduced Ex Vivo With A Lentiviral Vector Encoding The Codon-Optimized Version Of Pklr Gene

This article discusses clinical trials using a novel gene therapy approach for treating Pyruvate Kinase Deficiency (PKD). The therapy involves autologous CD34+ hematopoietic stem cells that have been genetically modified with a lentiviral vector carrying the codon-optimized version of the PKLR gene. These trials aim to evaluate the safety and potential effectiveness of this innovative treatment for both adult and pediatric patients with PKD, a rare inherited disorder affecting red blood cell survival.

Table of Contents

What is Pyruvate Kinase Deficiency (PKD)?

Pyruvate Kinase Deficiency (PKD) is a rare inherited metabolic disorder that affects the survival of red blood cells[1]. It is caused by mutations in the PKLR gene, which provides instructions for making an enzyme called pyruvate kinase. This enzyme is crucial for the normal functioning of red blood cells.

People with PKD may experience symptoms such as:

  • Severe anemia (low red blood cell count)
  • Fatigue
  • Shortness of breath
  • Jaundice (yellowing of the skin and eyes)
  • Enlarged spleen

Currently, treatments for PKD are limited and often include blood transfusions and management of complications. However, a new approach using gene therapy is being studied to potentially treat this condition more effectively.

Gene Therapy for PKD: An Innovative Approach

Researchers are developing a gene therapy treatment for PKD called RP-L301 (also known as Merilen)[2]. This innovative therapy involves:

  1. Collecting stem cells: Doctors collect a patient’s own blood-forming stem cells (called CD34+ cells) from their bloodstream.
  2. Modifying the cells: These cells are then modified in a laboratory using a lentiviral vector. This vector is a specially designed virus that carries a corrected version of the PKLR gene.
  3. Infusing the modified cells: The genetically modified cells are then infused back into the patient’s bloodstream.

The goal of this therapy is to provide the patient with cells that can produce functional pyruvate kinase enzyme, potentially reducing or eliminating the symptoms of PKD.

Clinical Trials: Evaluating Safety and Efficacy

RP-L301 is currently being studied in clinical trials to evaluate its safety and effectiveness[1][2]. These trials are designed to:

  • Assess the safety of infusing the genetically modified cells
  • Evaluate how long the modified cells persist in the body
  • Determine if the treatment leads to reduced need for blood transfusions
  • Monitor for any potential side effects or complications

Who Can Participate in the Clinical Trials?

The clinical trials are open to both adults and children with PKD, but there are specific eligibility criteria[2]. Some key inclusion criteria are:

  • Confirmed PKD diagnosis with a PKLR gene mutation
  • Age requirements:
    • Adults: 18 to 50 years old
    • Children: 8 to 17 years old
  • History of severe anemia or dependence on blood transfusions
  • Adequate organ function (heart, lungs, kidneys, liver)

There are also several exclusion criteria to ensure patient safety. It’s important to discuss with your doctor if you might be eligible for these trials.

The Treatment Process

The gene therapy treatment process involves several steps:

  1. Cell collection: The patient’s own blood-forming stem cells are collected through a process called leukapheresis.
  2. Cell modification: The collected cells are sent to a laboratory where they are genetically modified using the lentiviral vector carrying the corrected PKLR gene.
  3. Conditioning: The patient may receive chemotherapy to prepare their body for the modified cells.
  4. Infusion: The genetically modified cells are infused back into the patient’s bloodstream, similar to a blood transfusion.
  5. Recovery and monitoring: The patient is closely monitored for cell engraftment and any potential side effects.

Potential Benefits of the Gene Therapy

While the research is still ongoing, the potential benefits of this gene therapy for PKD patients could include[1][2]:

  • Reduced or eliminated need for blood transfusions
  • Improved hemoglobin levels
  • Better quality of life
  • Potential long-term correction of the genetic defect

Safety Monitoring and Long-Term Follow-Up

Patient safety is a top priority in these clinical trials. Researchers are carefully monitoring for any potential side effects or complications, including[1][2]:

  • Insertional mutagenesis: Checking if the genetic modification affects other genes
  • Replication-competent lentivirus (RCL): Ensuring the modified virus doesn’t replicate in the body
  • Immunogenicity: Monitoring for any immune reactions to the therapy
  • Long-term effects on overall survival and blood cell production

Patients who receive the gene therapy will be followed for an extended period to assess long-term safety and effectiveness of the treatment.

Aspect Details
Treatment Gene therapy using autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector carrying the codon-optimized PKLR gene
Target Condition Pyruvate Kinase Deficiency (PKD)
Trial Phase Phase I
Patient Age Groups Adults (18-50 years) and Pediatric (8-17 years)
Primary Objectives Evaluate long-term safety, transgene persistence, and potential clinical improvements
Key Eligibility Criteria Confirmed PKD diagnosis, severe anemia, specific transfusion requirements
Administration Method Intravenous infusion
Follow-up Duration Long-term (exact duration not specified)

FAQ

  • What is Pyruvate Kinase Deficiency (PKD)? Pyruvate Kinase Deficiency (PKD) is a rare inherited metabolic disorder that affects the enzyme pyruvate kinase, which is crucial for red blood cell survival. This condition leads to severe and often transfusion-dependent anemia.
  • What is the gene therapy being tested in these clinical trials? The gene therapy being tested involves using autologous CD34+ hematopoietic stem cells that have been genetically modified with a lentiviral vector carrying the codon-optimized version of the PKLR gene. This modified gene aims to correct the underlying genetic defect in PKD patients.
  • Who is eligible for these clinical trials? Eligibility includes patients with a confirmed PKD diagnosis and PKLR mutation, aged 8 years and older. Participants must have a history of severe and/or transfusion-dependent anemia, and meet specific criteria regarding hemoglobin levels and transfusion requirements.
  • What are the main objectives of these clinical trials? The primary objectives are to evaluate the long-term safety of the gene therapy, determine the persistence of the transgene in blood cells, assess potential correlations with clinical improvements, and monitor for any adverse events or complications related to the treatment.
  • How is the gene therapy administered to patients? The gene therapy is administered as an intravenous infusion of the patient's own (autologous) CD34+ cells that have been genetically modified outside the body (ex vivo) with the therapeutic lentiviral vector.

Ongoing Clinical Trials on Autologous Cd34+ Hematopoietic Stem Cells Transduced Ex Vivo With A Lentiviral Vector Encoding The Codon-Optimized Version Of Pklr Gene

  • Study on Gene Therapy for Pyruvate Kinase Deficiency Using Autologous CD34+ Cells in Adults and Children

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Long-Term Safety of Gene Therapy for Pyruvate Kinase Deficiency Using Autologous CD34+ Cells in Adults and Children

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Pyruvate Kinase Deficiency (PKD): A rare inherited metabolic disorder affecting the enzyme pyruvate kinase, which is essential for red blood cell survival. It leads to severe anemia and often requires regular blood transfusions.
  • Autologous: Referring to cells or tissues obtained from the same individual. In this context, it means using the patient's own cells for the gene therapy treatment.
  • CD34+ Hematopoietic Stem Cells: A type of stem cell found in bone marrow and blood that can develop into all types of blood cells. CD34 is a protein marker used to identify these cells.
  • Lentiviral Vector: A tool derived from a type of virus (lentivirus) used to deliver genetic material into cells. In gene therapy, it's used to introduce the corrected gene into the patient's cells.
  • Codon-optimized: A process of modifying a gene's DNA sequence to enhance its expression in the target cells without changing the protein it produces.
  • PKLR Gene: The gene that provides instructions for making the pyruvate kinase enzyme in red blood cells. Mutations in this gene cause Pyruvate Kinase Deficiency.
  • Ex vivo: Referring to procedures or experiments done outside of a living organism, typically on cells or tissues in a laboratory setting.
  • Transgene: A gene that has been transferred from one organism to another. In this case, it refers to the corrected PKLR gene introduced into the patient's cells.
  • Vector Copy Number (VCN): A measure of how many copies of the therapeutic gene have been integrated into the patient's cells.
  • Insertional Mutagenesis: A potential risk in gene therapy where the insertion of new genetic material into a cell's genome disrupts or alters the function of other genes.

References

  1. http://clinicaltrials.eu/trial/study-on-long-term-safety-of-gene-therapy-for-pyruvate-kinase-deficiency-using-autologous-cd34-cells-in-adults-and-children/
  2. http://clinicaltrials.eu/trial/study-on-gene-therapy-for-pyruvate-kinase-deficiency-using-autologous-cd34-cells-in-adults-and-children/